Nothing Special   »   [go: up one dir, main page]

SE9000333D0 - Monoklonal antikropp - Google Patents

Monoklonal antikropp

Info

Publication number
SE9000333D0
SE9000333D0 SE9000333A SE9000333A SE9000333D0 SE 9000333 D0 SE9000333 D0 SE 9000333D0 SE 9000333 A SE9000333 A SE 9000333A SE 9000333 A SE9000333 A SE 9000333A SE 9000333 D0 SE9000333 D0 SE 9000333D0
Authority
SE
Sweden
Prior art keywords
hiv
mabs
monoclonal antibody
antibody
immunization
Prior art date
Application number
SE9000333A
Other languages
English (en)
Inventor
Britta Wahren
Bror Morein
Lennart Aakerblom
Per Anders Broliden
Original Assignee
Britta Wahren
Bror Morein
Lennart Aakerblom
Anders Broliden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Britta Wahren, Bror Morein, Lennart Aakerblom, Anders Broliden filed Critical Britta Wahren
Priority to SE9000333A priority Critical patent/SE9000333D0/sv
Publication of SE9000333D0 publication Critical patent/SE9000333D0/sv
Priority to JP3503855A priority patent/JPH05503851A/ja
Priority to CA002073963A priority patent/CA2073963A1/en
Priority to EP91903427A priority patent/EP0523056A1/en
Priority to AU72198/91A priority patent/AU7219891A/en
Priority to PCT/SE1991/000071 priority patent/WO1991011198A1/en
Priority to NO92922878A priority patent/NO922878L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SE9000333A 1990-01-31 1990-01-31 Monoklonal antikropp SE9000333D0 (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE9000333A SE9000333D0 (sv) 1990-01-31 1990-01-31 Monoklonal antikropp
JP3503855A JPH05503851A (ja) 1990-01-31 1991-01-31 中和および／またはａｄｃｃ仲介モノクローナルｈｉｖ抗体
CA002073963A CA2073963A1 (en) 1990-01-31 1991-01-31 Neutralizing and/or adcc mediating monoclonal hiv antibody
EP91903427A EP0523056A1 (en) 1990-01-31 1991-01-31 Neutralizing and/or adcc mediating monoclonal hiv antibody
AU72198/91A AU7219891A (en) 1990-01-31 1991-01-31 Neutralizing and/or adcc mediating monoclonal hiv antibody
PCT/SE1991/000071 WO1991011198A1 (en) 1990-01-31 1991-01-31 Neutralizing and/or adcc mediating monoclonal hiv antibody
NO92922878A NO922878L (no) 1990-01-31 1992-07-20 Noeytralisering og/eller adcc-formidlende monoklonalt hiv-antistoff

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9000333A SE9000333D0 (sv) 1990-01-31 1990-01-31 Monoklonal antikropp

Publications (1)

Publication Number Publication Date
SE9000333D0 true SE9000333D0 (sv) 1990-01-31

Family

ID=20378406

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9000333A SE9000333D0 (sv) 1990-01-31 1990-01-31 Monoklonal antikropp

Country Status (6)

Country Link
EP (1) EP0523056A1 (sv)
JP (1) JPH05503851A (sv)
AU (1) AU7219891A (sv)
CA (1) CA2073963A1 (sv)
SE (1) SE9000333D0 (sv)
WO (1) WO1991011198A1 (sv)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5665569A (en) * 1991-08-22 1997-09-09 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
EP0662093B1 (en) * 1992-08-24 2001-05-30 Nissin Shokuhin Kabushiki Kaisha Hiv immunotherapeutics
US5618922A (en) * 1994-07-25 1997-04-08 Nissin Shokuhin Kabushiki Kaisha NM03 antibody materials and methods
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
DE60221705T2 (de) 2001-03-22 2008-06-05 The United States of America, represented by the Secretary, Dept. of Health and Human Services, the Natl. Institutes of Health, Office of Technology Transfer Glykosylierungsresistente cyanovirine und damit verbundene konjugate, zusammensetzungen, nukleinsäuren, vektoren, wirtszellen, herstellungsverfahren sowie verfahren zur verwendung nichtglykosylierter cyanovirine
US8481041B2 (en) 2005-04-06 2013-07-09 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
AU2007249488B2 (en) 2006-05-15 2011-11-10 Immunonomedics, Inc. Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
WO2016191481A1 (en) 2015-05-28 2016-12-01 Immunomedics, Inc. T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
ATE122237T1 (de) * 1987-05-29 1995-05-15 Tanox Biosystems Inc Hiv-1 neutralisierende monoklonale antikörper.
NL8702403A (nl) * 1987-10-09 1989-05-01 Stichting Centr Diergeneeskund Oligopeptiden en gebruik daarvan voor diagnostische en vaccinatiedoeleinden voor aids en arc.
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals

Also Published As

Publication number Publication date
WO1991011198A1 (en) 1991-08-08
EP0523056A1 (en) 1993-01-20
AU7219891A (en) 1991-08-21
JPH05503851A (ja) 1993-06-24
CA2073963A1 (en) 1991-08-01

Similar Documents

Publication Publication Date Title
SE9000333D0 (sv) Monoklonal antikropp
ATE237351T1 (de) Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
YU48250B (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
ATE233814T1 (de) Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
OA09802A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus.
JPS6485928A (en) Monoclonal antibody and peptide useful for therapy and diagnosis for hiv infection
EA199900067A1 (ru) Очищенный поверхностный антиген сперматозоидов, моноклональное антитело для него и их применения
ATE238420T1 (de) Rekombinanter humanisierter antikörper gegen menschlichen immunschwächevirus
ES2097759T3 (es) Anticuerpos especificos para el dominio de fijacion de cd4 de hiv.
DE69227500D1 (de) In der Therapie von einer HIV-1-Infektion verwendbare monoklonale Antikörper
EP0142345A3 (en) Anti-idiotypic vaccine employing anti-idiotypic monoclonal antibodies
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
WO2002057314A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes
DK0516135T3 (da) Humant immundefektvirus-relateret immunpræparat
DK1438970T3 (da) Fremgangsmåde til at inhibere HIV-associerede sygdomme ved hjælp af monoklonale antistoffer rettet mod sig-selv-rettede cytotoksiske celler
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
DK0537168T3 (da) Antigenet CTAA 28A32, som genkendes af MCA 28A32
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
SE8701765D0 (sv) Analysis method and means therefor
ATE207119T1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
ATE175357T1 (de) Empfängnisverhütender impfstoff
ATE102836T1 (de) Arzneimittel fuer die behandlung oder die verhuetung von infektionen mit hiv durch immunisierung, und verfahren zur herstellung.
Randall et al. Immunization with external and/or internal structural proteins protects mice from infection with the paramyxovirus SV5
Lafon et al. Production of human monoclonal antibodies neutralizing rabies virus: An alternative to rabies immune globulin of human blood donation
Isola Studies on the antigenic structure of herpes simplex virus glycoprotein D.